ES2194513T3 - Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. - Google Patents
Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas.Info
- Publication number
- ES2194513T3 ES2194513T3 ES99948982T ES99948982T ES2194513T3 ES 2194513 T3 ES2194513 T3 ES 2194513T3 ES 99948982 T ES99948982 T ES 99948982T ES 99948982 T ES99948982 T ES 99948982T ES 2194513 T3 ES2194513 T3 ES 2194513T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- component
- patopsychological
- neurological
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- ZHKQAQKGVKBJPP-YUZLPWPTSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2NC1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZHKQAQKGVKBJPP-YUZLPWPTSA-N 0.000 abstract 1
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 abstract 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 1
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 abstract 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 abstract 1
- 229940105150 5-methyltetrahydrofolic acid Drugs 0.000 abstract 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000008106 phosphatidylserines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición que comprende ingredientes activos y, opcionalmente, una o más substancias nutricionales, excipientes o auxiliares sólidos, líquidos y/o semilíquidos, caracterizada porque los ingredientes activos constan de a) un componente A que consta de una o más fosfatidil serinas, b) un componente B que consta de uno o más compuestos seleccionados entre ácido de dihidrofólico, ácido tetrahidrofólico, ácido 5-metiltetrahidrofólico, ácido 5-formiltetrahidrofólico, ácido 10-formiltetrahidrofólico, ácido 5, 10-metilenotetrahidrofólico, ácido 5, 10-meteniltetrahidrofólico o sus sales fisiológicamente aceptables c) un componente C que consta de uno o más compuestos seleccionados entre donadores de metilo y metileno, con la condición de que las fosfatidil serina y los compuestos del componente B no formen parte del componente C.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10623098P | 1998-10-30 | 1998-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2194513T3 true ES2194513T3 (es) | 2003-11-16 |
Family
ID=22310256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99948982T Expired - Lifetime ES2194513T3 (es) | 1998-10-30 | 1999-10-13 | Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6514973B1 (es) |
| EP (1) | EP1124559B1 (es) |
| JP (1) | JP2002528507A (es) |
| AT (1) | ATE235244T1 (es) |
| AU (1) | AU6202299A (es) |
| CA (1) | CA2348390C (es) |
| DE (1) | DE69906345T2 (es) |
| ES (1) | ES2194513T3 (es) |
| WO (1) | WO2000025793A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739313A (en) | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
| US6806363B1 (en) | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
| US7591995B2 (en) | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
| TWI228512B (en) | 2000-10-25 | 2005-03-01 | Mayo Foundation | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| US20020176881A1 (en) * | 2001-01-26 | 2002-11-28 | George Verlaan | Rehydration composition |
| KR20040000413A (ko) * | 2001-03-26 | 2004-01-03 | 기벤티스 게엠베하 | 인지력을 증강시키는 식품 |
| EP1302196A1 (de) * | 2001-10-16 | 2003-04-16 | Habinger, René, Ing. Mag. | Intelligenzfördernde Zahncreme |
| EP3184107A1 (en) * | 2002-06-19 | 2017-06-28 | N.V. Nutricia | Method and preparation for treating metabolic stress |
| US7033612B2 (en) * | 2003-01-03 | 2006-04-25 | Kang David S | Composition and method for treating age-related disorders |
| IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
| US20050130937A1 (en) * | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
| US8052992B2 (en) * | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
| US7935365B2 (en) * | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| EP1645276A1 (en) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Treatment of neurodegenerative disorders |
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| ZA200704140B (en) * | 2004-11-16 | 2008-08-27 | Limerick Neurosciences Inc | Methods and compositions for treating pain |
| JP5559701B2 (ja) | 2008-01-30 | 2014-07-23 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | イミダゾリウム及びイミダゾリニウム化合物で線維症及び癌を治療する方法 |
| WO2009123569A1 (en) * | 2008-03-31 | 2009-10-08 | Agency For Science, Technology And Research | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| US8546104B2 (en) * | 2008-08-07 | 2013-10-01 | Lipogen Ltd. | Processes for the preparation of phosphatide salts |
| CA3162668A1 (en) * | 2010-02-12 | 2011-08-18 | Gentelon, Inc. | Compositions and methods for treating depression |
| WO2014018873A2 (en) * | 2012-07-27 | 2014-01-30 | Chemic Laboratories Inc. | Compositions comprising folic acid derivatives. their preparations and methods of use |
| CA3042699A1 (en) | 2016-11-03 | 2018-08-09 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
| CA3121235A1 (en) | 2018-11-30 | 2020-06-04 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for reducing major thrombotic events in cancer patients |
| EP4501315A1 (en) | 2023-08-04 | 2025-02-05 | Lesaffre et Compagnie | Liquid formulations of folates |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC2041A1 (fr) * | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | Agents anti-atherogenic |
| IT1229517B (it) * | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| DE4117629A1 (de) * | 1991-05-29 | 1992-12-03 | Max Planck Gesellschaft | Phospatidylserine |
| US5997915A (en) * | 1996-01-31 | 1999-12-07 | South Alabama Medical Science Foundation | Compositions for human and animal consumption containing reduced folates and methods for making and using same |
| US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
| AU2470299A (en) * | 1998-01-27 | 1999-08-09 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
-
1999
- 1999-10-13 WO PCT/EP1999/007688 patent/WO2000025793A1/en not_active Ceased
- 1999-10-13 AT AT99948982T patent/ATE235244T1/de not_active IP Right Cessation
- 1999-10-13 DE DE69906345T patent/DE69906345T2/de not_active Expired - Lifetime
- 1999-10-13 CA CA002348390A patent/CA2348390C/en not_active Expired - Fee Related
- 1999-10-13 AU AU62022/99A patent/AU6202299A/en not_active Abandoned
- 1999-10-13 EP EP99948982A patent/EP1124559B1/en not_active Expired - Lifetime
- 1999-10-13 JP JP2000579233A patent/JP2002528507A/ja active Pending
- 1999-10-13 ES ES99948982T patent/ES2194513T3/es not_active Expired - Lifetime
- 1999-10-13 US US09/830,352 patent/US6514973B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2348390A1 (en) | 2000-05-11 |
| JP2002528507A (ja) | 2002-09-03 |
| US6514973B1 (en) | 2003-02-04 |
| EP1124559A1 (en) | 2001-08-22 |
| DE69906345D1 (de) | 2003-04-30 |
| EP1124559B1 (en) | 2003-03-26 |
| DE69906345T2 (de) | 2004-02-12 |
| CA2348390C (en) | 2008-11-25 |
| WO2000025793A1 (en) | 2000-05-11 |
| AU6202299A (en) | 2000-05-22 |
| ATE235244T1 (de) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2194513T3 (es) | Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. | |
| AR010348A1 (es) | Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen | |
| CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| ES2058185T3 (es) | Derivados de camptotecina y procedimiento para su preparacion. | |
| ES2145774T3 (es) | Derivados de adenosina que tienen actividad agonista en a2. | |
| DK0960107T3 (da) | 6-Thiosubstituerede paclitaxeler | |
| ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR005703A1 (es) | Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| PT971717E (pt) | Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois | |
| AR035284A1 (es) | Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion | |
| AR029941A1 (es) | Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| ECSP11005642A (es) | Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas | |
| PA8457001A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol | |
| ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
| DE69803773D1 (de) | Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion | |
| MX9300399A (es) | Derivados heterotriciclicos. | |
| MX9300558A (es) | Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene. | |
| ES2052484T1 (es) | N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR025379A1 (es) | 9a-azalidas con actividad antibacteriana. | |
| AR023644A1 (es) | 3-aril-pirazoles substituidos, procedimiento para su obtencion, procedimiento para la lucha contra plantas indeseables, empleo de los mismos contra plantasindeseables y/o como fungicida, y composicion para el tratamiento de plantas | |
| SE8403659D0 (sv) | Synergistic pharmaceutical composition | |
| ES2054904T3 (es) | Procedimiento para la preparacion de peptidos con actividad inhibidora de sistemas enzimaticos. |